Anti-neurotensin mab for the treatment of cancer

The present invention relates to a neutralising antibody which is capable of binding to neurotensin with high affinity. The antibody of the present invention neutralises the activity of neurotensin, in particular the oncogenic activities of neurotensin. In particular, the present invention relates to a neutralising antibody which binds to the human neurotensin long fragment, and having a heavy chain variable region which comprises a H-CDR1 region having at least 90% of identity with SEQ ID NO:2 in the, a H- CDR2 region having at least 90% of identify with SEQ ID NO:3 and a H-CDR3 region having at least 90% of identity with SEQ ID NO:4; and a light chain variable region comprising a L-CDR1 region having 90% of identity with SEQ ID NO:6, a L-CDR2 having 90% of identity with SEQ ID NO:7 and a L-CDR3 region having 90% of identity with SEQ ID NO: 8. The present invention also provides the use of such antibodies in the treatment of cancer.

Patent Application number: European Procedure (Patents) (EPA) - 02 Juin 2014 - 14 305 825.3
Publications:
Cancer Letters 444 (2019) 147–161

Reference:

BIO14015-T1

Business Developper
contact
Anne COCHI
Business Development Manager
Patent filling date: 02-06-2014
Rare disease: No
Second indication: No

You might also be interested in